Health state utilities associated with weight loss in type 2 diabetes and obesity

References

• Borisenko O, Lukyanov V, Ahmed AR. Cost-utility analysis of bariatric surgery. Br J Surg. 2018;105(10):1328–1337.
   PubMed Web of Science ®Google Scholar
• Hagberg LA, Brekke HK, Bertz F, et al. Cost-utility analysis of a randomized controlled weight loss trial among lactating overweight/obese women. BMC Public Health. 2014;14:38.
   PubMedGoogle Scholar
• Stanford FC, Alfaris N, Gomez G, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Surg Obes Relat Dis. 2017;13(3):491–500.
   PubMed Web of Science ®Google Scholar
• Castilla I, Mar J, Valcárcel-Nazco C, et al. Cost-utility analysis of gastric bypass for severely obese patients in Spain. Obes Surg. 2014;24(12):2061–2068.
   PubMed Web of Science ®Google Scholar
• McEwen LN, Coelho RB, Baumann LM, et al. The cost, quality of life impact, and cost-utility of bariatric surgery in a managed care population. Obes Surg. 2010;20(7):919–928.
   PubMed Web of Science ®Google Scholar
• Xu H, Li Y, Du S, et al. Cost-utility and cost-benefit analyses of school-based obesity prevention program. BMC Public Health. 2020;20(1):1608.
   PubMed Web of Science ®Google Scholar
• Assumpcao RP, Bahia LR, da Rosa MQM, et al. Cost-utility of gastric bypass surgery compared to clinical treatment for severely obese with and without diabetes in the perspective of the Brazilian public health system. Obes Surg. 2019;29(10):3202–3211.
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, UKPDS 72 United Kingdom Prospective Diabetes Study, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48(5):868–877.
   PubMed Web of Science ®Google Scholar
• Gu S, Shi L, Shao H, et al. Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. BMC Med. 2020;18(1):378.
   PubMed Web of Science ®Google Scholar
• Men P, Liu T, Zhai S. Empagliflozin in type 2 diabetes mellitus patients with high cardiovascular risk: a model-based cost-utility analysis in China. Diabetes Metab Syndr Obes. 2020;13:2823–2831.
   PubMedGoogle Scholar
• Brazier J, Ara R, Rowen D, et al. A review of generic preference-based measures for use in cost-effectiveness models. Pharmacoeconomics. 2017;35(Suppl 1):21–31.
   PubMedGoogle Scholar
• Ackermann RT, Edelstein SL, Narayan KMV, Diabetes Prevention Program Research Group, et al. Changes in health state utilities with changes in body mass in the diabetes prevention program. Obesity. 2009;17(12):2176–2181.
   PubMed Web of Science ®Google Scholar
• Al-Rubaye AKQ, Johansson K, Alrubaiy L. The association of health behavioral risk factors with quality of life in Northern Sweden-a cross-sectional survey. J Gen Fam Med. 2020;21(5):167–177.
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217–230.
   PubMed Web of Science ®Google Scholar
• Hakim Z, Wolf A, Garrison LP. Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics. 2002;20(6):393–404.
   PubMed Web of Science ®Google Scholar
• Kiadaliri AA, Gerdtham U-G, Eliasson B, et al. Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden. Int J Environ Res Public Health. 2014;11(5):4939–4952.
   PubMed Web of Science ®Google Scholar
• Kontodimopoulos N, Pappa E, Chadjiapostolou Z, et al. Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications. Eur J Health Econ. 2012;13(1):111–120.
   PubMed Web of Science ®Google Scholar
• Kortt MA, Clarke PM. Estimating utility values for health states of overweight and obese individuals using the SF-36. Qual Life Res. 2005;14(10):2177–2185.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Morgan CL, Morrissey M, et al. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes. Diabet Med. 2005;22(11):1482–1486.
   PubMed Web of Science ®Google Scholar
• Lin VW, Wong ES, Wright A, et al. Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach. Value Health. 2013;16(5):823–829.
   PubMed Web of Science ®Google Scholar
• Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in dutch patients with type 2 diabetes. Diabetes Care. 2002;25(3):458–463.
   PubMed Web of Science ®Google Scholar
• Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18.
   PubMed Web of Science ®Google Scholar
• Trevino RP, Pham TH, Edelstein SL. Obesity and preference-weighted quality of life of ethnically diverse middle school children: the HEALTHY study. J Obes. 2013;2013:206074.
   PubMedGoogle Scholar
• Yfantopoulos J, Chantzaras A. Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications. Eur J Health Econ. 2020;21(5):729–743.
   PubMed Web of Science ®Google Scholar
• Kamradt M, Krisam J, Kiel M, et al. Health-Related quality of life in primary care: Which aspects matter in multimorbid patients with type 2 diabetes mellitus in a community setting? PLOS One. 2017; 12(1) :e0170883.
   PubMed Web of Science ®Google Scholar
• Bentley TGK, Palta M, Paulsen AJ, et al. Race and gender associations between obesity and nine health-related quality-of-life measures. Qual Life Res. 2011;20(5):665–674.
   PubMed Web of Science ®Google Scholar
• Campbell JA, Hensher M, Neil A, et al. An exploratory study of long-term publicly waitlisted bariatric surgery patients' quality of life before and 1 year after bariatric surgery, and considerations for healthcare planners. PharmacoEconomics Open. 2018;2(1):63–76.
   PubMed Web of Science ®Google Scholar
• Fermont JM, Blazeby JM, Rogers CA, By-Band-Sleeve Study Management Group, et al. The EQ-5D-5L is a valid approach to measure health related quality of life in patients undergoing bariatric surgery. PLOS One. 2017;12(12):e0189190.
   PubMed Web of Science ®Google Scholar
• Lester EL, Padwal R, Majumdar SR, et al. Association of preference-based health-related quality of life with weight loss in obese adults. Value Health. 2017;20(4):694–698.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Buse JB, Mann JFE, LEADER Publication Committee for the LEADER Trial Investigators, et al. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. Diabetes Obes Metab. 2019;21(3):525–532.
   PubMed Web of Science ®Google Scholar
• Rothberg AE, McEwen LN, Kraftson AT, et al. The impact of weight loss on health-related quality-of-life: implications for cost-effectiveness analyses. Qual Life Res. 2014;23(4):1371–1376.
   PubMed Web of Science ®Google Scholar
• Wang P, Luo N, Tai ES, et al. The EQ-5D-5L is more discriminative than the EQ-5D-3L in patients with diabetes in Singapore. Value Health Reg Issues. 2016;9:57–62.
   PubMedGoogle Scholar
• Zhang P, Brown MB, Bilik D, et al. Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from translating research into action for diabetes (TRIAD). Diabetes Care. 2012;35(11):2250–2256.
   PubMed Web of Science ®Google Scholar
• Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30(7):1267–1273.
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007;16(7):1251–1265.
   PubMed Web of Science ®Google Scholar
• Matza LS, Yurgin N, Boye KS, et al. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23(9):2051–2062.
   PubMed Web of Science ®Google Scholar
• Rajan N, Boye KS, Gibbs M, et al. Utilities for type 2 diabetes treatment-related attributes in a South Korean and Taiwanese population. Value Health Reg Issues. 2016;9:67–71.
   PubMedGoogle Scholar
• Wee CC, Davis RB, Huskey KW, et al. Quality of life among obese patients seeking weight loss surgery: the importance of obesity-related social stigma and functional status. J Gen Intern Med. 2013;28(2):231–238.
   PubMed Web of Science ®Google Scholar
• Wee CC, Hamel MB, Davis RB, et al. Assessing the value of weight loss among primary care patients. J Gen Intern Med. 2004;19(12):1206–1211.
   PubMed Web of Science ®Google Scholar
• Olofsson S, Norrlid H, Persson U. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden. J Med Econ. 2016;19(10):945–958.
   PubMed Web of Science ®Google Scholar
• Ridderstrale M, et al. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health Qual Life Outcomes. 2016;14:13.
   PubMed Web of Science ®Google Scholar
• Lonneman DJ, Jr., Rey JA, McKee BD. Phentermine/topiramate extended-release capsules (qsymia) for weight loss. PT. 2013;38(8):446–452.
   PubMedGoogle Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
   PubMed Web of Science ®Google Scholar
• Dahl D, Onishi Y, Norwood PAUL, et al. 80-LB: tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS-5). Am Diab Assoc 81st Sci Sessions. 2021;70(Supplement 1): 80-LB.
   Google Scholar
• Frias JP, Davies MJ, Rosenstock J, et al. 84-LB: efficacy and safety of tirzepatide versus semaglutide once weekly as add-on therapy to metformin in people with type 2 diabetes (SURPASS-2). Am Diab Assoc 81st Sci Sessions. 2021;70(Supplement 1):84-LB.
   Google Scholar
• Ludvik B, Giorgino F, Jodar E, et al. 78-LB: efficacy and safety of tirzepatide, a dual GIP/GLP-1 receptor agonist, compared to insulin degludec in patients with type 2 diabetes (SURPASS-3) [abstract], in. Am Diab Assoc 81st Sci Sessions. 2021;70(Supplement 1):78-LB.
   Google Scholar
• Rosenstock J, Wysham CH, Frias JP, et al. 100-OR: efficacy and safety of once weekly tirzepatide, a dual GIP/GLP-1 receptor agonist versus placebo as monotherapy in people with type 2 diabetes (SURPASS-1) [abstract]. Am Diab Assoc 81st Sci Sessions. 2021;70(Supplement 1):100-OR.
   Google Scholar
• Cvetanovic G, Stojiljković M, Miljkovic M. Estimation of the relationship between hypoglycemia and body mass index on health-related quality of life, in patients with type 2 diabetes mellitus. Vojnosanitetski Pregled. 2016;74:98–98.
   Web of Science ®Google Scholar
• Wee C, Jones D, Davis R, et al. Understanding patients' value of weight loss and expectations for bariatric surgery. Obes Surg. 2006;16(4):496–500.
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Stewart KD, et al. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. J Med Econ. 2019;22(8):806–813.
   PubMed Web of Science ®Google Scholar
• Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–230.
   PubMed Web of Science ®Google Scholar
• Matza L, Boye K, Jordan J, et al. Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. PPA. 2018;12:971–979.
   Google Scholar
• Matza LS, Boye KS, Stewart KD, et al. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res. 2017;17(1):774.
   PubMed Web of Science ®Google Scholar
• Matza LS, Cutts KN, Stewart KD, et al. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Qual Life Res. 2021;30(7):2033–2043.
   PubMed Web of Science ®Google Scholar
• Courcoulas AP, King WC, Belle SH, et al. Seven-Year weight trajectories and health outcomes in the longitudinal assessment of bariatric surgery (LABS) study. JAMA Surg. 2018;153(5):427–434.
   PubMed Web of Science ®Google Scholar
• Maciejewski ML, Arterburn DE, Van Scoyoc L, et al. Bariatric surgery and long-term durability of weight loss. JAMA Surg. 2016;151(11):1046–1055.
   PubMed Web of Science ®Google Scholar
• Welbourn R, Hollyman M, Kinsman R, et al. Bariatric surgery worldwide: Baseline demographic description and one-year outcomes from the fourth IFSO global registry report 2018. Obes Surg. 2019;29(3):782–795.
   PubMed Web of Science ®Google Scholar
• Rabin R, Gudex C, Selai C, et al. From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire. Value Health. 2014;17(1):70–76.
   PubMed Web of Science ®Google Scholar
• van Hout B, Janssen MF, Feng Y-S, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715.
   PubMed Web of Science ®Google Scholar
• Janssen MF, Lubetkin EI, Sekhobo JP, et al. The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus. Diabet Med. 2011;28(4):395–413.
   PubMed Web of Science ®Google Scholar
• Sach TH, Barton GR, Doherty M, et al. The relationship between body mass index and health-related quality of life: comparing the EQ-5D, EuroQol VAS and SF-6D. Int J Obes. 2007;31(1):189–196.
   Web of Science ®Google Scholar
• Keating CL, Peeters A, Swinburn BA, et al. Utility-based quality of life associated with overweight and obesity: the Australian Diabetes, Obesity, and Lifestyle Study. Obesity. 2013;21(3):652–655.
   PubMed Web of Science ®Google Scholar
• Schunk M, Reitmeir P, Schipf S, et al. Health-related quality of life in women and men with type 2 diabetes: a comparison across treatment groups. J Diabetes Compl. 2015;29(2):203–211.
   PubMed Web of Science ®Google Scholar
• Wiklund M, Olsén MF. Physical function and health related quality of life before and 18 months after bariatric surgery. TOOBESJ. 2015;7(1):12–16.
   Google Scholar